MCID: HYP056
MIFTS: 66

Hypoglycemia

Categories: Blood diseases, Endocrine diseases, Metabolic diseases

Aliases & Classifications for Hypoglycemia

MalaCards integrated aliases for Hypoglycemia:

Name: Hypoglycemia 12 74 29 54 6 42 43 15 71
Hypoglycaemia 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:9993
ICD9CM 34 251.2
MeSH 43 D007003
NCIt 49 C3126
SNOMED-CT 67 66694000
ICD10 32 E16.2
UMLS 71 C0020615

Summaries for Hypoglycemia

MedlinePlus : 42 Hypoglycemia means low blood glucose, or blood sugar. Your body needs glucose to have enough energy. After you eat, your blood absorbs glucose. If you eat more sugar than your body needs, your muscles, and liver store the extra. When your blood sugar begins to fall, a hormone tells your liver to release glucose. In most people, this raises blood sugar. If it doesn't, you have hypoglycemia, and your blood sugar can be dangerously low. Signs include Hunger Shakiness Dizziness Confusion Difficulty speaking Feeling anxious or weak In people with diabetes, hypoglycemia is often a side effect of diabetes medicines. Eating or drinking something with carbohydrates can help. If it happens often, your health care provider may need to change your treatment plan. You can also have low blood sugar without having diabetes. Causes include certain medicines or diseases, hormone or enzyme deficiencies, and tumors. Laboratory tests can help find the cause. The kind of treatment depends on why you have low blood sugar. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hypoglycemia, also known as hypoglycaemia, is related to hyperinsulinemic hypoglycemia, familial, 2 and hyperinsulinemic hypoglycemia, familial, 7, and has symptoms including sugar craving An important gene associated with Hypoglycemia is G6PC (Glucose-6-Phosphatase Catalytic Subunit), and among its related pathways/superpathways are Metabolism and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs lanreotide and Linagliptin have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and liver, and related phenotypes are shRNA abundance <= 50% and homeostasis/metabolism

Disease Ontology : 12 A glucose metabolism disease that is characterized by abnormally low levels of blood glucose.

Wikipedia : 74 Hypoglycemia, also known as low blood sugar, is a fall in blood sugar to levels below normal. This may... more...

Related Diseases for Hypoglycemia

Diseases related to Hypoglycemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1116)
# Related Disease Score Top Affiliating Genes
1 hyperinsulinemic hypoglycemia, familial, 2 35.2 KCNJ11 INS ABCC8
2 hyperinsulinemic hypoglycemia, familial, 7 34.9 SLC16A1 KCNJ11 HADH GLUD1 GCK ABCC8
3 hyperinsulinemic hypoglycemia, familial, 6 34.8 SLC16A1 INS HADH GLUD1 GCK ABCC8
4 hyperinsulinemic hypoglycemia 34.5 SLC16A1 KCNJ11 INSR INS HADH GLUD1
5 fasting hypoglycemia 34.3 INSR GYS2 GLUD1 CRH ACADM
6 hirata disease 33.8 INS GCG
7 glycogen storage disease type 0 33.8 GYS2 AGL
8 carnitine palmitoyltransferase ii deficiency, infantile 33.6 SLC25A20 HADH CPT2 CPT1A ACADVL ACADM
9 fructose-1,6-bisphosphatase deficiency 33.3 GCK GCG G6PC FBP1
10 carnitine-acylcarnitine translocase deficiency 33.3 SLC25A20 CPT2 CPT1A
11 glycogen storage disease ia 33.2 GCG G6PC FBP1 AGL
12 carnitine palmitoyltransferase i deficiency 33.2 CPT2 CPT1A ACADVL ACADM
13 beckwith-wiedemann syndrome 33.1 SLC16A1 KCNJ11 INS ABCC8
14 3-hydroxyacyl-coa dehydrogenase deficiency 33.0 HADH GLUD1 GCK ACADVL ACADM
15 acyl-coa dehydrogenase, very long-chain, deficiency of 33.0 SLC25A20 HADH CPT2 ACADVL ACADM
16 acyl-coa dehydrogenase, medium-chain, deficiency of 33.0 SLC25A20 HADH CPT2 ACADVL ACADM
17 multiple acyl-coa dehydrogenase deficiency 32.9 SLC25A20 HADH CPT2 ACADVL ACADM
18 hyperinsulinism 32.8 SLC16A1 KCNJ11 INSR INS HADH GLUD1
19 long-chain 3-hydroxyacyl-coa dehydrogenase deficiency 32.7 HADH ACADVL ACADM
20 glycogen storage disease vi 32.7 GYS2 G6PC AGL
21 epiphyseal dysplasia, multiple, with early-onset diabetes mellitus 32.6 KCNJ11 INS ABCC8
22 carnitine deficiency, systemic primary 32.5 SLC25A20 HADH CPT2 ACADVL ACADM
23 acyl-coa dehydrogenase, short-chain, deficiency of 32.4 HADH CPT2 ACADVL ACADM
24 donohue syndrome 32.3 KCNJ11 INSR INS GCK
25 insulinoma 32.1 INS GCK GCG ABCC8
26 hyperglycemia 32.0 KCNJ11 INSR INS GCK GCG G6PC
27 islet cell tumor 31.9 INSR INS GCG
28 hypoglycemic coma 31.6 INS GCG
29 diabetes mellitus 31.5 KCNJ11 INSR INS GCK GCG G6PC
30 diabetes mellitus, ketosis-prone 31.5 KCNJ11 INS GCG ABCC8
31 gestational diabetes 31.3 KCNJ11 INSR INS GCK GCG ABCC8
32 insulin-like growth factor i 31.3 INSR INS AKT2
33 maturity-onset diabetes of the young 31.2 KCNJ11 INS GCK GCG ABCC8
34 glycogen storage disease 31.2 INS GYS2 G6PC CPT2 AGL
35 glucose intolerance 31.0 KCNJ11 INSR INS GCK GCG ABCC8
36 reye syndrome 30.9 CPT2 ACADVL ACADM
37 munchausen by proxy 30.9 KCNJ11 GCK ABCC8
38 maturity-onset diabetes of the young, type 3 30.9 KCNJ11 INS GCK ABCC8
39 pituitary gland disease 30.8 INS GCG CRH
40 monocarboxylate transporter 1 deficiency 30.8 SLC16A1 INS GLUD1
41 neonatal diabetes mellitus 30.7 KCNJ11 INS GCK GCG ABCC8
42 asphyxia neonatorum 30.7 SLC16A1 KCNJ11 INS HADH ABCC8
43 diabetes mellitus, noninsulin-dependent 30.7 KCNJ11 INSR INS GCK GCG G6PC
44 lipoid congenital adrenal hyperplasia 30.7 INS CRH ACADM
45 monogenic diabetes 30.7 KCNJ11 INS GCK ABCC8
46 transient neonatal diabetes mellitus 30.6 KCNJ11 INS GCK ABCC8
47 diabetes mellitus, permanent neonatal 30.6 KCNJ11 INS GCK GCG ABCC8
48 maple syrup urine disease 30.6 HADH GLUD1 ACADM
49 maturity-onset diabetes of the young, type 2 30.6 KCNJ11 INS GCK ABCC8
50 acute insulin response 30.6 KCNJ11 INS GCG ABCC8

Comorbidity relations with Hypoglycemia via Phenotypic Disease Network (PDN): (show all 30)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alzheimer Disease
Benign Essential Hypertension Bronchitis
Cerebral Atherosclerosis Decubitus Ulcer
Deficiency Anemia Diabetic Polyneuropathy
Encephalopathy Familial Atrial Fibrillation
First-Degree Atrioventricular Block Generalized Atherosclerosis
Heart Disease Hypertension, Essential
Hypoglycemic Coma Hypothyroidism
Intermediate Coronary Syndrome Iron Deficiency Anemia
Kidney Disease Microvascular Complications of Diabetes 1
Microvascular Complications of Diabetes 7 Mitral Valve Disease
Peripheral Vascular Disease Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder
Sinoatrial Node Disease Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Hypoglycemia:



Diseases related to Hypoglycemia

Symptoms & Phenotypes for Hypoglycemia

UMLS symptoms related to Hypoglycemia:


sugar craving

GenomeRNAi Phenotypes related to Hypoglycemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.32 ACADM ACADVL AGL CPT2 FBP1 G6PC

MGI Mouse Phenotypes related to Hypoglycemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.3 ABCC8 ACADM ACADVL AGL AKT2 CPT1A
2 cardiovascular system MP:0005385 10.1 ACADM ACADVL CPT1A CPT2 GCK GYS2
3 endocrine/exocrine gland MP:0005379 10.07 ABCC8 AKT2 CRH GCK GLUD1 HADH
4 adipose tissue MP:0005375 10.03 ACADVL AKT2 CRH HADH INS INSR
5 liver/biliary system MP:0005370 10.03 ACADM ACADVL AGL AKT2 CRH G6PC
6 mortality/aging MP:0010768 9.97 ACADM ACADVL AGL AKT2 CPT1A CPT2
7 muscle MP:0005369 9.56 ACADM ACADVL AGL AKT2 GYS2 INS
8 renal/urinary system MP:0005367 9.17 CRH G6PC GCK HADH INS INSR

Drugs & Therapeutics for Hypoglycemia

Drugs for Hypoglycemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 530)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
lanreotide Approved Phase 4 108736-35-2
2
Linagliptin Approved Phase 4 668270-12-0 10096344
3
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
4
Racepinephrine Approved Phase 4 329-65-7 838
5
Ethanol Approved Phase 4 64-17-5 702
6
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
7
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
8
Gliclazide Approved Phase 4 21187-98-4 3475
9
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
10
Fosaprepitant Approved Phase 4 172673-20-0 219090
11
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
12
Verapamil Approved Phase 4 52-53-9 2520
13
Caffeine Approved Phase 4 58-08-2 2519
14
Simvastatin Approved Phase 4 79902-63-9 54454
15
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
16
Tolbutamide Approved, Investigational Phase 4 64-77-7 5505
17
Chlorzoxazone Approved Phase 4 95-25-0 2733
18
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
19
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
20
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
21
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
22
Esmolol Approved Phase 4 81147-92-4, 103598-03-4 59768
23
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
24
Haloperidol Approved Phase 4 52-86-8 3559
25
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
26
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
27
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
28
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
29
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
30
Alogliptin Approved Phase 4 850649-61-5 11450633
31
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
32
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
33
Glucagon Approved Phase 4 16941-32-5
34
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
35
Empagliflozin Approved Phase 4 864070-44-0
36
Saxagliptin Approved Phase 4 361442-04-8 11243969
37
Insulin detemir Approved Phase 4 169148-63-4 5311023
38
Glimepiride Approved Phase 4 93479-97-1 3476
39
tannic acid Approved Phase 4 1401-55-4
40
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
41
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
42
Canagliflozin Approved Phase 4 842133-18-0
43
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
44
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
45
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
46
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
47 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
48
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
49
Methyltestosterone Approved Phase 4 58-18-4 6010
50
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 6013 10204

Interventional clinical trials:

(show top 50) (show all 1686)
# Name Status NCT ID Phase Drugs
1 Comparison of Two Strategies of Hypoglycemia Correction in ICU Unknown status NCT01387477 Phase 4 Lactate;Glucose
2 Randomized, Open Prospective Study of the Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2 Unknown status NCT02719756 Phase 4 Metformin;Dapagliflozin;Metformin up-titration
3 The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes Unknown status NCT02307695 Phase 4 Saxagliptin;Insulin
4 Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia? Unknown status NCT00472875 Phase 4 Glibenclamide
5 Impact of Insulin Detemir Versus Insulin Glargine on Glycaemic Control and Metabolism During Exercise in Type 1 Diabetes Unknown status NCT01440439 Phase 4 Insulin glargine;Insulin detemir
6 Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery Unknown status NCT01841359 Phase 4 Pramlintide
7 Is Insulin NovoRapid Better Than Actrapid for Treating Type 1 Diabetic Patients When Simultaneously, Daily Adjusting the Insulin Dose? Unknown status NCT00145353 Phase 4 Insulin NovoRapid versus Actrapid
8 Real-Time Continuous Glucose Monitoring in Pre-School Children With Type-1 Diabetes Mellitus Unknown status NCT01016457 Phase 4
9 Treatment of Hypoglycemia With Glucagon Among Patients With Type 1 Diabetes Mellitus Unknown status NCT02232971 Phase 4 Glucagon
10 Basal-bolus Insulin Therapy With Insulin Degludec and Insulin Aspart Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study Unknown status NCT03244241 Phase 4 Insulin Degludec 100 UNT/ML [Tresiba]
11 Effects of Intensive Insulin Therapy on Mortality, Morbidity and Long Term Neurologic Outcome in Neurosurgical Intensive Care Patients Unknown status NCT00505505 Phase 4 Insulin (Actrapid)
12 A Randomized, Open, Controlled, Parallel Group Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy Unknown status NCT03320031 Phase 4 Linagliptin;Humalog Mix 75/25
13 The Efficacy and Safety of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase 4 Inhibitor Added to Premix Insulin Injection Twice Daily in Uncontrolled Type 2 Diabetes Patients Unknown status NCT03458715 Phase 4 SGLT2 inhibitor (Empagliflozin 25 MG);DPP4 inhibitor (Linagliptin 5 MG)
14 Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus Unknown status NCT01206647 Phase 4 Metformin and Saxagliptin
15 Optimal Insulin Correction Factor in Post- High Intensity Exercise Hyperglycemia in Adults With Type 1 Diabetes: The FIT Study Unknown status NCT03057470 Phase 4 50% bolus insulin correction;100% bolus insulin correction;150% bolus insulin correction
16 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4 metformin and sitagliptin;insulin glargine and insulin lispro;metformin and sitagliptin;insulin glargine and insulin lispro
17 Organization Program of DiabEtes INsulIN ManaGement: An Open, Multi-center, Prospective, Randomized, 16-week, Controlled Clinical Study Unknown status NCT01338376 Phase 4 Scilin®M30
18 A Pilot Study of Outpatient Discharge Therapy With Saxagliptin + Metformin XR or Sulphonylurea for Recently Diagnosed Type 2 Diabetes Presenting With Severe Hyperglycemia Unknown status NCT01267448 Phase 4 Glipizide XL;Saxagliptin + Metformin XR;Metformin XR
19 Explore the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin in Chinese Type 2 Diabetes by CGMS Unknown status NCT02438397 Phase 4 premix insulin;metformin;Acarbose
20 Treatment With Lanreotide Autogel (Somatostatin Analogue) in Patients With Congenital Hyperinsulinism of Infancy Already Treated With Somatostatin Analog by Pump Unknown status NCT01070758 Phase 4 Lanreotide autogel
21 A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients Unknown status NCT00336310 Phase 4 Repaglinide
22 GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients Unknown status NCT01592279 Phase 4 liraglutide;Insulin injections
23 The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) Unknown status NCT02501850 Phase 4 Liraglutide;metformin
24 Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan Unknown status NCT03349840 Phase 4 Insulin Degludec U100;Insulin Glargine
25 The Therapeutic Effects of Combination of Insulin With Berberine on the Patients With Stess Hyperlipemia:a Prospective, Double Blind, Randomized, Placebo-controlled, Single-center Clinical Trial Unknown status NCT02806999 Phase 4 Berberine; Insulin;Insulin
26 Randomized, Long-Term Study About the Effects of Analogue Versus Human Insulin Based Regimens (Insulin Detemir and Aspart Versus NPH- and Regular Human Insulin) on Metabolic Control and Myocardial Function in People With Type 2 Diabetes. Unknown status NCT00747409 Phase 4 insulin aspart and detemir (NovoRapid, Levemir);human regular insulin and NPH insulin (Actrapid, Protaphne)
27 Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study Unknown status NCT02690883 Phase 4 Exenatide;Lispro
28 A Phase IV, Multicenter, Randomized, Active Comparator Controlled Study of the Addition of Pioglitazone Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Alogliptin Unknown status NCT02426294 Phase 4 Pioglitazone;Glimepiride
29 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics- Double Blind Placebo Controlled Study Unknown status NCT00845936 Phase 4 Metformin
30 Improving Glycaemic Control in Malaysian Patients With Type 2 Diabetes Mellitus With Insulin Pump Therapy Unknown status NCT03112538 Phase 4 Multiple daily injections of insulin
31 Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study—STAT Study Unknown status NCT03143816 Phase 4 Technosphere insulin
32 Healthy Heart Study: Can Insulin Glargine Improve Myocardial Function in Patients With Type 2 Diabetes and Coronary Artery Disease? A Prospective, Randomized, Controlled Clinical Study With Blinded Analysis of Ultrasound Data Unknown status NCT01035528 Phase 4 insulin glargine;metformin
33 An Open-label, Randomized , Phase 4 Study to Compare the Different Efficacies of α-glucosidase Inhibitor and Sulfonylurea on Improvement of Intestinal Microbiome and Serum Incretins in Patients With Type 2 Diabetes Unknown status NCT01758471 Phase 4 Glipizide;Acarbose
34 Effect of Dapagliflozin on Cardio-Metabolic Risk Factors in Patients With Type-2 Diabetes Unknown status NCT03377335 Phase 4 Dapagliflozin 10mg;Metformin
35 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
36 Absorption and Utilization of a Mixed Meal in Type 1 Diabetes: Creation of a Biological and In Silico Biobank for the Optimization of Artificial Pancreas Systems. A Pilot Study. Unknown status NCT01800734 Phase 4
37 Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes Unknown status NCT02372955 Phase 4 dapagliflozin;glimpiride
38 Effect of Linagliptin on Intestinal Triglyceride-rich-lipoprotein Metabolism in Type 2 Diabetic Patients Unknown status NCT02280174 Phase 4 linagliptin
39 Effect of Anti-diabetic Drugs on Glycemic Variability. A Comparison Between Gliclazide MR (Modified Release) and Dapagliflozin on Glycemic Variability Measured by Continuous Glucose Monitoring (CGM) in Patients With Uncontrolled Type 2 Diabetes Unknown status NCT02925559 Phase 4 Dapagliflozin;Gliclazide MR
40 Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin. Unknown status NCT00700856 Phase 4 add-on pioglitazone;add-on sulphonylurea
41 Can Hypoglycaemia Awareness Be Restored in Individuals With Type 1 Diabetes and Severe Hypoglycaemia Employing Optimised Subcutaneous Insulin Regime or Continuous Subcutaneous Insulin Infusion Pump Completed NCT00360984 Phase 4 insulin glargine
42 The Effect of Insulin Analogues and Human Insulin on the Incidence of Severe Hypoglycaemia in Hypoglycaemia Prone Type 1 Diabetic Patients Completed NCT00346996 Phase 4 insulin levemir / aspart;human insulin /insulin isophane
43 The Effect of Insulin Degludec on Risk of Symptomatic Nocturnal Hypoglycaemia in Subjects With Type 1 Diabetes and High Risk of Nocturnal Severe Hypoglycaemia Completed NCT02192450 Phase 4 Insulin aspart/glargine;Insulin aspart/degludec
44 The Late Effects of Ethanol Intake on the Glucose Response to Subcutaneous Glucagon in Type 1 Diabetes Completed NCT02881060 Phase 4
45 A Phase IIIb/IV, Multinational, Multicentre, Randomised, Open Study to Establish the Optimal Method for Initiating and Maintaining Lantus® (Insulin Glargine) Therapy Based on a Comparison of Two Treatment Algorithms to Determine Optimal Metabolic Outcomes, Safety, and Satisfaction in Subjects With Type 1 Diabetes Mellitus/ "HALT" Sub-study: Multicentre, Open Clinical Trial to Assess the Effect of Insulin Glargine on Symptomatic Hypoglycaemia, Fear of Hypoglycaemia and Quality of Life in Patients With Type 1 Diabetes Completed NCT00390728 Phase 4 Insulin Glargine
46 A Double-blind, Randomised, Crossover Study to Investigate the Difference in Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 Compared to Biphasic Human Insulin 30 in Patients With Well-controlled Type 2 Diabetes Completed NCT01487798 Phase 4 biphasic human insulin 30;biphasic insulin aspart 30
47 National (Brazil), Phase IV, Multicentric, Open Label, Parallel, Comparative Study of the Use of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure. Completed NCT01122979 Phase 4 INSULIN GLARGINE;NPH insulin (insulin isophane);INSULIN GLULISINE;Regular insulin
48 Glucagon Efficiency After High and Low Carbohydrate Diet Completed NCT02578498 Phase 4
49 Efficacy of a Continuous GLP-1 Infusion in Comparison to a Structured Insulin Infusion Protocol to Reach Normoglycemia in Non-Fasted Type 2 Diabetic Patients Completed NCT00859079 Phase 4 GLP-1;Human regular insulin intravenously
50 Randomized, Double-blind, Placebo-controlled Trial on the Effectiveness and Safety of Dapagliflozin for Blood Glucose Control During Glucocorticoid Treatment for Acute Exacerbation COPD Completed NCT02253121 Phase 4 Dapagliflozin;Sliding scale insulin

Search NIH Clinical Center for Hypoglycemia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


DEXTROSE 100% PWDR
Diazoxide
Glucagon
Glucose
GLUCOSE LIQUID

Cochrane evidence based reviews: hypoglycemia

Genetic Tests for Hypoglycemia

Genetic tests related to Hypoglycemia:

# Genetic test Affiliating Genes
1 Hypoglycemia 29

Anatomical Context for Hypoglycemia

MalaCards organs/tissues related to Hypoglycemia:

40
Brain, Testes, Liver, Pancreas, Pituitary, Kidney, Heart

Publications for Hypoglycemia

Articles related to Hypoglycemia:

(show top 50) (show all 38355)
# Title Authors PMID Year
1
Benefits and harms of intensive glycemic control in patients with type 2 diabetes. 61 42
31690574 2019
2
Glucagon nasal powder (Baqsimi) for severe hypoglycemia. 61 42
31599866 2019
3
HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study. 61 42
31462492 2019
4
IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. 54 61
20527023 2010
5
[A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)]. 54 61
20519186 2010
6
Prolonged survival and improved glycemia in BioBreeding diabetic rats after early sustained exposure to glucagon-like peptide 1. 54 61
20527046 2010
7
Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. 54 61
20463416 2010
8
Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension. 54 61
20200307 2010
9
Diazoxide-responsive hyperinsulinemic hypoglycemia caused by HNF4A gene mutations. 54 61
20164212 2010
10
Glucose transporter type 1 deficiency: ketogenic diet in three patients with atypical phenotype. 54 61
19515520 2010
11
Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. 54 61
20380655 2010
12
Brain glucosamine boosts protective glucoprivic feeding. 54 61
20179264 2010
13
Transient salt wasting in POMC-deficiency due to infection induced stress. 54 61
19998238 2010
14
A case of a giant phyllodes tumor of the breast with hypoglycemia caused by high-molecular-weight insulin-like growth factor II. 54 61
19259766 2010
15
Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. 54 61
20206728 2010
16
Solitary fibrous tumor of soft tissue: a case report and immunohistochemical study. 54 61
20340008 2010
17
Type B insulin resistance syndrome with systemic lupus erythematosus. 54 61
20129024 2010
18
Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs. 54 61
20107298 2010
19
Hypoglycemia due to ectopic secretion of insulin-like growth factor-I in a patient with an isolated sarcoidosis of the spleen. 54 61
20081321 2010
20
Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes. 54 61
20107301 2010
21
[Late onset 3-HMG-CoA lyase deficiency: a rare but treatable disorder]. 54 61
19932602 2010
22
A novel mutation in the glycogen synthase 2 gene in a child with glycogen storage disease type 0. 54 61
20051115 2010
23
Novel FBP1 gene mutations in Arab patients with fructose-1,6-bisphosphatase deficiency. 54 61
19259699 2009
24
In vivo phosphoenolpyruvate carboxykinase promoter mapping identifies disrupted hormonal synergism as a target of inflammation during sepsis in mice. 54 61
19821526 2009
25
Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes. 54 61
19707744 2009
26
Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists. 54 61
19925391 2009
27
DPP-4 inhibitors in clinical practice. 54 61
19940419 2009
28
Hyperinsulinaemic hypoglycaemia associated with a heterozygous missense mutation of R1174W in the insulin receptor (IR) gene. 54 61
19170714 2009
29
Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. 54 61
19790256 2009
30
No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects. 54 61
19094067 2009
31
Treatment of dwarfism with recombinant human insulin-like growth factor-1. 54 61
19946434 2009
32
Malignant solitary fibrous tumor: report of 3 cases with unusual features. 54 61
19349855 2009
33
New therapies for diabesity. 54 61
19793506 2009
34
Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. 54 61
19638470 2009
35
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. 54 61
19801361 2009
36
Hypoglycemia with intensive insulin therapy in critically ill patients: predisposing factors and association with mortality. 54 61
19623047 2009
37
Beta-human chorionic gonadotropin production associated with phyllodes tumor of the breast: an unusual paraneoplastic phenomenon. 54 61
19624411 2009
38
Defining the importance of daily glycemic control and implications for type 2 diabetes management. 54 61
19820277 2009
39
Selecting among ADA/EASD tier 1 and tier 2 treatment options. 54 61
19744422 2009
40
Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. 54 61
19624785 2009
41
Hemangiopericytoma-associated hypoglycemia improved by glucocorticoid therapy: a case report. 54 61
19387873 2009
42
[Diagnosis of glycogen storage disease type IIIA by detecting glycogen debranching enzyme activity, glycogen content and structure in muscle]. 54 61
19951495 2009
43
Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans. 54 61
19470629 2009
44
Delay in blood glucose monitoring during an insulin infusion protocol is associated with increased risk of hypoglycemia in intensive care units. 54 61
19670374 2009
45
Two novel POLG mutations causing hepatic mitochondrial DNA depletion with recurrent hypoketotic hypoglycaemia and fatal liver dysfunction. 54 61
19195941 2009
46
Factors determining inadequate hypoglycaemia during insulin tolerance testing (ITT) after pituitary surgery. 54 61
19178524 2009
47
3-Hydroxyacyl-coenzyme A dehydrogenase deficiency and hyperinsulinemic hypoglycemia: characterization of a novel mutation and severe dietary protein sensitivity. 54 61
19417036 2009
48
Hypoglycemia from IGF2 overexpression associated with activation of fetal promoters and loss of imprinting in a metastatic hemangiopericytoma. 54 61
19383775 2009
49
[A case of retroperitoneal solitary fibrous tumor associated with hypoglycemia]. 54 61
19673425 2009
50
Lys169 of human glucokinase is a determinant for glucose phosphorylation: implication for the atomic mechanism of glucokinase catalysis. 54 61
19617908 2009